RegenxBio gets positive interim data for eye disease treatment

Rockville ’s RegenxBio Inc. (NASDAQ: RGNX) has more work to do before its eye disease treatment candidate can reach patients — but it’s already seeing some promise. The company’s ongoing phase 1 and phase 2a trial for the gene therapy program, RGX-314, found the majority of patients with wet age-rela ted macular degeneration required fewer anti-VEGF injections — the current standard of care — to manage the condition, and experienced improvement in vision and retinal thickness when they…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news